FOXO3 and SMAD4 |
forkhead box O3 |
SMAD family member 4 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Signaling by NODAL
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by BMP
- Transcriptional regulation of pluripotent stem cells
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
GSK3A and MYC |
glycogen synthase kinase 3 alpha |
v-myc avian myelocytomatosis viral oncogene homolog |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- XBP1(S) activates chaperone genes
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- IRE1alpha activates chaperones
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Unfolded Protein Response (UPR)
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- binding of TCF/LEF:CTNNB1 to target gene promoters
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Mitotic G1-G1/S phases
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- S Phase
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- Signaling by WNT in cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
GSK3B and MYC |
glycogen synthase kinase 3 beta |
v-myc avian myelocytomatosis viral oncogene homolog |
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- binding of TCF/LEF:CTNNB1 to target gene promoters
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Mitotic G1-G1/S phases
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- S Phase
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- Signaling by WNT in cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
|
|
|
NR4A1 and RBL1 |
nuclear receptor subfamily 4, group A, member 1 |
retinoblastoma-like 1 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Nuclear Receptor transcription pathway
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- Generic Transcription Pathway
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Mitotic G1-G1/S phases
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- G1 Phase
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- G0 and Early G1
- Loss of Function of TGFBR1 in Cancer
- Cell Cycle, Mitotic
- Cyclin D associated events in G1
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
HRAS and RASSF1 |
Harvey rat sarcoma viral oncogene homolog |
Ras association (RalGDS/AF-6) domain family member 1 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- SHC-mediated cascade
- MEK activation
- FCERI mediated MAPK activation
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- p38MAPK events
- EPH-Ephrin signaling
- SOS-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- SHC-mediated signalling
- Signaling by PDGF
- DAP12 interactions
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Signaling by FGFR mutants
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-2 signaling
- Interleukin-3, 5 and GM-CSF signaling
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Ras activation uopn Ca2+ infux through NMDA receptor
- Adaptive Immune System
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- Axon guidance
- IRS-mediated signalling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- IRS-related events triggered by IGF1R
- EGFR Transactivation by Gastrin
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- RAF phosphorylates MEK
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Post NMDA receptor activation events
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- SHC-mediated signalling
- IRS-related events
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- ARMS-mediated activation
- SHC1 events in EGFR signaling
- RAF activation
- IRS-mediated signalling
- FRS2-mediated cascade
- Activation of RAS in B cells
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- Constitutive Signaling by EGFRvIII
|
|
- Hexane-1,6-Diol
- Trifluoroethanol
- Guanosine-5\'-Triphosphate
- Guanosine-5\'-Diphosphate
- N,N\'-DIMETHYL-N-(ACETYL)-N\'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
|
|
|
|
HSP90AA1 and MYC |
heat shock protein 90kDa alpha (cytosolic), class A member 1 |
v-myc avian myelocytomatosis viral oncogene homolog |
- HSF1 activation
- Regulatory RNA pathways
- Signaling by EGFRvIII in Cancer
- Regulation of PLK1 Activity at G2/M Transition
- Influenza Life Cycle
- Influenza Viral RNA Transcription and Replication
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Uptake and actions of bacterial toxins
- EPH-Ephrin signaling
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Fcgamma receptor (FCGR) dependent phagocytosis
- Recruitment of mitotic centrosome proteins and complexes
- Regulation of actin dynamics for phagocytic cup formation
- vRNP Assembly
- Influenza Infection
- Signaling by ERBB2
- Signaling by VEGF
- Signaling by EGFR in Cancer
- Sema3A PAK dependent Axon repulsion
- Mitotic G2-G2/M phases
- Uptake and function of diphtheria toxin
- PIWI-interacting RNA (piRNA) biogenesis
- Organelle biogenesis and maintenance
- Axon guidance
- Attenuation phase
- G2/M Transition
- VEGFA-VEGFR2 Pathway
- HSF1-dependent transactivation
- EPHA-mediated growth cone collapse
- Metabolism of nitric oxide
- VEGFR2 mediated vascular permeability
- Loss of Nlp from mitotic centrosomes
- Scavenging by Class F Receptors
- eNOS activation and regulation
- Innate Immune System
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Assembly of the primary cilium
- Cellular response to heat stress
- Anchoring of the basal body to the plasma membrane
- Cell Cycle, Mitotic
- eNOS activation
- Loss of proteins required for interphase microtubule organization from the centrosome
- Centrosome maturation
- Constitutive Signaling by EGFRvIII
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- Cyclin E associated events during G1/S transition
- binding of TCF/LEF:CTNNB1 to target gene promoters
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- RNF mutants show enhanced WNT signaling and proliferation
- G1/S Transition
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Mitotic G1-G1/S phases
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- S Phase
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Cyclin A:Cdk2-associated events at S phase entry
- Signaling by WNT in cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
- Rifabutin
- Nedocromil
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
- Geldanamycin
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
- 17-Dmag
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
- Adenosine-5\'-Diphosphate
- 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
- 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
- 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
- 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
- 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
- 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
- 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
- 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
- N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
- 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
- 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
- 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
- (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
- 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
- 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
- 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
- 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
- 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
- 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
- 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
|
|
|
|
IRF3 and RBL1 |
interferon regulatory factor 3 |
retinoblastoma-like 1 |
- Negative regulators of RIG-I/MDA5 signaling
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
- Interferon gamma signaling
- Activated TLR4 signalling
- TRAF3-dependent IRF activation pathway
- ZBP1(DAI) mediated induction of type I IFNs
- IRF3 mediated activation of type 1 IFN
- STING mediated induction of host immune responses
- Interferon alpha/beta signaling
- Innate Immune System
- ISG15 antiviral mechanism
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Interferon Signaling
- Cytokine Signaling in Immune system
- MyD88-independent cascade
- Factors involved in megakaryocyte development and platelet production
- Antiviral mechanism by IFN-stimulated genes
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Regulation of innate immune responses to cytosolic DNA
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- TRAF6 mediated IRF7 activation
- IRF3-mediated induction of type I IFN
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Mitotic G1-G1/S phases
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- G1 Phase
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- G0 and Early G1
- Loss of Function of TGFBR1 in Cancer
- Cell Cycle, Mitotic
- Cyclin D associated events in G1
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
ITK and SMAD4 |
IL2-inducible T-cell kinase |
SMAD family member 4 |
- TCR signaling
- Generation of second messenger molecules
- Fc epsilon receptor (FCERI) signaling
- FCERI mediated Ca+2 mobilization
- Innate Immune System
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by BMP
- Transcriptional regulation of pluripotent stem cells
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
LCK and SMAD2 |
LCK proto-oncogene, Src family tyrosine kinase |
SMAD family member 2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Nef and signal transduction
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- CD28 co-stimulation
- Host Interactions of HIV factors
- CD28 dependent PI3K/Akt signaling
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- TCR signaling
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Downstream TCR signaling
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- HIV Infection
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Nef Mediated CD4 Down-regulation
- Innate Immune System
- Signalling by NGF
- Generation of second messenger molecules
- Translocation of ZAP-70 to Immunological synapse
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- CTLA4 inhibitory signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- CD28 dependent Vav1 pathway
- PECAM1 interactions
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- PD-1 signaling
- GPVI-mediated activation cascade
- Phosphorylation of CD3 and TCR zeta chains
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Dasatinib
- {4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- (4-{2-Acetylamino-2-[1-(3-Carbamoyl-4-Cyclohexylmethoxy-Phenyl)-Ethylcarbamoyl}-Ethyl}-2-Phosphono-Phenoxy)-Acetic Acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
|
|
|
|
PDGFRA and TGFBR2 |
platelet-derived growth factor receptor, alpha polypeptide |
transforming growth factor, beta receptor II (70/80kDa) |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Becaplermin
- Imatinib
- Sunitinib
- Pazopanib
- Regorafenib
- Ponatinib
|
|
|
|
PIK3R1 and TGFBR2 |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
transforming growth factor, beta receptor II (70/80kDa) |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
|
PIK3R2 and TGFBR2 |
phosphoinositide-3-kinase, regulatory subunit 2 (beta) |
transforming growth factor, beta receptor II (70/80kDa) |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- G alpha (q) signalling events
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- Signaling by Rho GTPases
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Rho GTPase cycle
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- PI3K Cascade
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
MAPK1 and SP1 |
mitogen-activated protein kinase 1 |
Sp1 transcription factor |
- phospho-PLA2 pathway
- Ca-dependent events
- Signaling by FGFR in disease
- Cellular Senescence
- ERKs are inactivated
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- RSK activation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- PLC beta mediated events
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- G-protein mediated events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Recycling pathway of L1
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Post NMDA receptor activation events
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- ERK2 activation
- Nuclear Events (kinase and transcription factor activation)
|
- Loss of Function of TGFBR2 in Cancer
- PPARA activates gene expression
- Metabolism of lipids and lipoproteins
- Cellular Senescence
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Oncogene Induced Senescence
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Generic Transcription Pathway
- TGFBR2 MSI Frameshift Mutants in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- Activation of gene expression by SREBF (SREBP)
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- SMAD4 MH2 Domain Mutants in Cancer
|
- Isoproterenol
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Purvalanol
- SB220025
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
|
|
|
|
MAPK1 and TGIF1 |
mitogen-activated protein kinase 1 |
TGFB-induced factor homeobox 1 |
- phospho-PLA2 pathway
- Ca-dependent events
- Signaling by FGFR in disease
- Cellular Senescence
- ERKs are inactivated
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- RSK activation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- PLC beta mediated events
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- G-protein mediated events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Recycling pathway of L1
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Post NMDA receptor activation events
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- ERK2 activation
- Nuclear Events (kinase and transcription factor activation)
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Loss of Function of TGFBR1 in Cancer
- Generic Transcription Pathway
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
- Isoproterenol
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Purvalanol
- SB220025
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
|
|
|
|
AP2B1 and SMAD4 |
adaptor-related protein complex 2, beta 1 subunit |
SMAD family member 4 |
- Retrograde neurotrophin signalling
- Axon guidance
- HIV Infection
- Nef Mediated CD8 Down-regulation
- L1CAM interactions
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- Recycling pathway of L1
- EPH-ephrin mediated repulsion of cells
- MHC class II antigen presentation
- EPH-Ephrin signaling
- Nef Mediated CD4 Down-regulation
- EGFR downregulation
- Signalling by NGF
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- Host Interactions of HIV factors
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- beta-catenin independent WNT signaling
- Signaling by EGFR
- WNT5A-dependent internalization of FZD4
- Signaling by EGFR in Cancer
- PCP/CE pathway
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by BMP
- Transcriptional regulation of pluripotent stem cells
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
AKT1 and BRCA1 |
v-akt murine thymoma viral oncogene homolog 1 |
breast cancer 1, early onset |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Activation of BH3-only proteins
- Signaling by Wnt
- Platelet Aggregation (Plug Formation)
- Signaling by EGFRvIII in Cancer
- AKT phosphorylates targets in the cytosol
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- Regulation of beta-cell development
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Signaling by PDGF
- Downregulation of ERBB2:ERBB3 signaling
- DAP12 interactions
- Regulation of mRNA stability by proteins that bind AU-rich elements
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Activation of BAD and translocation to mitochondria
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by VEGF
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Regulation of gene expression in beta cells
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- Translocation of GLUT4 to the plasma membrane
- deactivation of the beta-catenin transactivating complex
- VEGFA-VEGFR2 Pathway
- Metabolism of nitric oxide
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- VEGFR2 mediated vascular permeability
- Downstream signaling of activated FGFR
- Programmed Cell Death
- XAV939 inhibits tankyrase, stabilizing AXIN
- eNOS activation and regulation
- Intrinsic Pathway for Apoptosis
- Butyrate Response Factor 1 (BRF1) destabilizes mRNA
- Innate Immune System
- Signalling by NGF
- CTLA4 inhibitory signaling
- AKT-mediated inactivation of FOXO1A
- Integrin alphaIIb beta3 signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Negative regulation of the PI3K/AKT network
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- eNOS activation
- TCF dependent signaling in response to WNT
- KSRP destabilizes mRNA
- GPVI-mediated activation cascade
- Signaling by WNT in cancer
|
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
- Adenosine triphosphate
- Arsenic trioxide
- Inositol 1,3,4,5-Tetrakisphosphate
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
|
|
|
|
APP and TGFBR2 |
amyloid beta (A4) precursor protein |
transforming growth factor, beta receptor II (70/80kDa) |
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
CAMK2G and SMAD4 |
calcium/calmodulin-dependent protein kinase II gamma |
SMAD family member 4 |
- Interferon Signaling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- CREB phosphorylation through the activation of Ras
- Trafficking of AMPA receptors
- Interferon gamma signaling
- HSF1-dependent transactivation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- CREB phosphorylation through the activation of CaMKII
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
- Unblocking of NMDA receptor, glutamate binding and activation
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Ras activation uopn Ca2+ infux through NMDA receptor
- Post NMDA receptor activation events
- Transmission across Chemical Synapses
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by BMP
- Transcriptional regulation of pluripotent stem cells
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
CD59 and SMAD4 |
CD59 molecule, complement regulatory protein |
SMAD family member 4 |
- Regulation of Complement cascade
- Complement cascade
- Innate Immune System
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by BMP
- Transcriptional regulation of pluripotent stem cells
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
CDC42 and ARHGEF7 |
cell division cycle 42 |
Rho guanine nucleotide exchange factor (GEF) 7 |
- Signaling by GPCR
- Costimulation by the CD28 family
- Axon guidance
- DCC mediated attractive signaling
- Signaling by EGFRvIII in Cancer
- VEGFA-VEGFR2 Pathway
- Inactivation of Cdc42 and Rac
- Rho GTPase cycle
- EPHB-mediated forward signaling
- EPH-Ephrin signaling
- G alpha (12/13) signalling events
- Sema4D in semaphorin signaling
- Netrin-1 signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- Sema4D induced cell migration and growth-cone collapse
- Regulation of actin dynamics for phagocytic cup formation
- Innate Immune System
- EGFR downregulation
- CDO in myogenesis
- Semaphorin interactions
- CD28 co-stimulation
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Factors involved in megakaryocyte development and platelet production
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- CD28 dependent Vav1 pathway
- Signaling by EGFR
- GPCR downstream signaling
- Myogenesis
- Signaling by VEGF
- Signaling by Rho GTPases
- Signaling by EGFR in Cancer
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- Signaling by Robo receptor
- Adaptive Immune System
|
- EGFR downregulation
- Signaling by GPCR
- Signalling by NGF
- Axon guidance
- Cell death signalling via NRAGE, NRIF and NADE
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- p75 NTR receptor-mediated signalling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by EGFRvIII in Cancer
- Rho GTPase cycle
- Signaling by EGFR
- GPCR downstream signaling
- Ephrin signaling
- NRAGE signals death through JNK
- Signaling by Rho GTPases
- Signaling by EGFR in Cancer
- EPH-Ephrin signaling
- G alpha (12/13) signalling events
|
|
|
|
|